Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MK-3475A |
Synonyms | |
Therapy Description |
Limited information is currently available on MK-3475A, a putative formulation of Keytruda (pembrolizumab) with MK-5180 (Apr 2023). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MK-3475A | MK 3475A|MK3475A | Limited information is currently available on MK-3475A, a putative formulation of Keytruda (pembrolizumab) with MK-5180 (Apr 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06099782 | Phase II | MK-3475A Pembrolizumab | A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) | Active, not recruiting | USA | TUR | POL | NZL | FRA | AUS | ARG | 3 |
NCT06698042 | Phase III | Pembrolizumab MK-3475A | A Clinical Study of MK-3475A to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) | Recruiting | ROU | POL | ESP | 2 |
NCT06504394 | Phase II | MK-3475A | A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Hyaluronidase (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65) | Recruiting | USA | POL | NZL | ESP | 2 |